AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program

21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 […]

Texas Medical Center forms ‘BioBridge’ with United Kingdom

By Christine Hall | September 12, 2018 The Texas Medical Center and the Department for International Trade in the United Kingdom formed a landmark BioBridge agreement Wednesday to provide a gateway for the advancement of life sciences between the two entities in the areas of innovation and research. The BioBridge, which included more than 18 months of preparation […]

The PKG has been recommended by two separate panel experts for routine management of Parkinson’s

Company update: Global Kinetics Corporation hits significant clinical milestones on its trajectory to revolutionise the treatment of Parkinson’s disease Leading digital health company Global Kinetics’ ground-breaking PKGTM technology recommended by world leading Parkinson’s experts ahead of achieving a key milestone on the path to USA reimbursement PORTSMOUTH, NH USA, LONDON, UK, and MELBOURNE, Australia, August […]

Adherium Launches Hailie™ Solution Direct-to-Consumer in the U.S. for Better Asthma and COPD Management

13 Aug 2018 San Mateo, CA – August 13th, 2018: Adherium (ASX: ADR), a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie™ solution in the U.S., following its recent Food and Drug Administration (FDA) 510(k) over-the-counter clearance to enable sales direct to consumers. The Hailie solution […]

AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in Life-Threatening Burns

FDA approves expansion of program to include up to 108 patients and 26 U.S. burn centers Valencia, Calif., USA, and Melbourne, Australia, 9 August 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number of patients who may be […]

Destiny Pharma notes FDA statement on their focus to enable new approaches to fight AMR

Brighton, United Kingdom – 14 June 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), notes the FDA Commissioner, Scott Gottlieb M.D.’s further announcements this week outlining the regulator’s support of new incentives for companies developing novel […]

AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

PUBLIC COMPANY INFORMATION: “Furthermore, treatment with AB-PA01 was safe and well-tolerated. In this case study, bacteriophage therapy has demonstrated to hold much promise for patients with cystic fibrosis suffering from multidrug resistant pulmonary bacterial infections.” AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today […]

Adherium to Present at the Chardan Digital Health Conference

15 May 2018 San Mateo, CA – May 1, 2018: Adherium, an award-winning digital health company that improves medication adherence and patient outcomes, today announced the Company will be participating in the upcoming Chardan Digital Health Conference in San Francisco, CA on Tuesday, May 22, 2018. Arik Anderson, CEO, is scheduled to provide a business overview […]

AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus

PUBLIC COMPANY INFORMATION: NYSEAM: APHB “We are pleased and encouraged by the support from the NIAID and its commitment to studying the role of bacteriophage in combating infectious diseases” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will […]

RECELL Successful Pivotal Trial Data Presented at ABA Day 3

Valencia, Calif., USA, and Melbourne, Australia, 13 April 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that its pivotal, controlled clinical trial in the treatment of deep full-thickness (third-degree) burns with the RECELL® Autologous Cell Harvesting Device achieved its co-primary endpoints, demonstrating a statistically significant reduction in donor skin requirements versus standard of […]